HF
NAMS icon

HRT Financial’s NewAmsterdam Pharma NAMS Stock Holding History

HRT Financial’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,208
Closed -$474K – 3396
2025
Q2 		$474K Sell
26,208
-6,434
-20% -$117K ﹤0.01% 1632
2025
Q1 		$668K Buy
+32,642
New +$726K ﹤0.01% 1312
2024
Q4 		– Sell
-37,601
Closed -$624K – 2953
2024
Q3 		$624K Buy
+37,601
New +$651K ﹤0.01% 1485

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HRT Financial's NAMS Position: Q3 2025 in Review

HRT Financial sold out of NewAmsterdam Pharma (NAMS) in Q3 2025, closing a stake of 26,208 shares — an estimated $474K sold.

HRT Financial first reported a position in NAMS in Q3 2024 and held it in 3 quarters. The position peaked at $668K in Q1 2025. 137 funds tracked by Wall St. Rank hold NAMS as of Q3 2025.

  • HRT Financial reported no remaining NewAmsterdam Pharma position as of Q3 2025 after selling out during the quarter.
  • HRT Financial sold 26,208 NewAmsterdam Pharma shares in Q3 2025, an estimated $474K.
  • HRT Financial first reported a position in NewAmsterdam Pharma in Q3 2024 and held it in 3 quarters.
  • HRT Financial's NewAmsterdam Pharma position peaked at $668K in Q1 2025.
  • 137 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.